Navigation Links
Chiasma Grants Option to License Transient Permeability Enhancer (TPE) Technology for Small Molecule Products
Date:1/19/2010

JERUSALEM, Jan. 19 /PRNewswire/ -- Chiasma, Inc., a privately held biopharma company, announced today that it has granted Novartis an option to obtain exclusive worldwide rights to develop and commercialize the Company's Transient Permeability Enhancer (TPE) technology for use with certain related small molecule products either in development or currently marketed by Novartis. In a separate but related agreement, the MPM Bio IV NVS Strategic Fund L.P. made an equity investment in Chiasma.

The two companies have initiated a feasibility program funded by Novartis. Should Novartis exercise the option, it would assume the global clinical development, manufacturing, regulatory submissions and commercialization of the products containing the TPE technology. Chiasma would receive payments upon the option exercise and upon successful completion of certain development and regulatory milestones. In addition, Chiasma would be eligible to receive a percentage of any incremental profits generated as a result of the incorporation of the TPE technology into these Novartis products. Additional terms were not disclosed.

Fredric Price, Chairman and CEO of Chiasma said, "Our strategy is two-fold: (1) to develop our own proprietary products and seek out partnerships after demonstrating clinical effectiveness and safety; and (2) to enter into arrangements with companies whose important drugs could benefit from the TPE technology.

"Our internally-developed pipeline is focused on developing new therapies by selecting approved macromolecules that are currently available in injectable form, changing the route of administration to oral and evaluating them for new indications, thereby creating new drugs that will take advantage of the 505(b)(2) regulatory route in the US and similar regulations in other countries.'/>"/>

SOURCE Chiasma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
2. European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL)
3. Pfenex Grants Exclusive License to Merck & Co., Inc. for the Production of Proteins for Undisclosed Vaccine Program
4. FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology
5. SRI International Receives National Institutes of Health Grants to Develop Improved Tomographic Imaging Technology
6. The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies
7. U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine)
8. FDA Grants GeoVax Labs, Inc. Request For Pre-IND Meeting
9. Ganeden Biotech Announces Grants for Early Investigators to Research Probiotic GanedenBC30
10. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
11. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... -- Abaxis, Inc. (NasdaqGS: ABAX ), a medical ... financial results for the first fiscal quarter ended June ... Revenues of $47.5 million, up 10% over last year,s ... 50% over last year,s comparable quarter. Revenues ... up 20% over last year,s comparable quarter. , ...
(Date:7/24/2014)... 24, 2014  IRIDEX Corporation (NASDAQ: IRIX ... quarter 2014 financial results after the market closes on ... the release, the Company will host a conference call ... Time on Thursday, July 31, 2014 ... business developments. Interested parties may access the ...
(Date:7/24/2014)... , July 24, 2014 Omnicell, Inc. ... of medication and supply management solutions and analytics ... Thursday, July 31, to discuss the Company,s Second ... Second Quarter 2014 earnings conference call and webcastWhen: ... , Randall Lipps, chairman, president and chief executive ...
Breaking Medicine Technology:Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2
... , June 28 Preliminary results of ... and hypertension demonstrated that the investigational triple combination therapy ... resulted in a statistically significant greater Least Squares (LS) ... 12 (37.9/22.0 mm Hg versus 26.4-28.0/14.7-17.6 mm Hg, P ...
... Tolerx, Inc., a biopharmaceutical company developing novel ... T cell activity, today announced the initiation of a ... in autoimmune new-onset type 1 diabetes. The confirmatory Phase ... For Early or New-Onset Type 1 Diabetes) and immediately ...
Cached Medicine Technology:New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 2New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 3New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 4New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 5New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 6New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 7Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes 2Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes 3Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes 4
(Date:7/25/2014)... As reported by the Statesman Journal in the ... (7/20), police in Salem, MA as well as several other ... heroin epidemic that has taken many lives during the past ... case in which police were able to make two arrests ... pretending to be the victim and claiming to want to ...
(Date:7/25/2014)... (HealthDay News) -- Seniors are more easily distracted during ... study finds. "Almost any type of memory test ... of 25 on," study co-author Randi Martin, professor of ... release. However, Martin said, this study shows that ... older adults compared with younger adults. The study ...
(Date:7/25/2014)... 25, 2014 Reproductive Science Center (RSC) ... Dr. Kerri Luzzo, Lead Physician at RSC Rhode Island, ... professional accomplishments in fertility care and community outreach issued ... 10th Annual PBN Awards ceremony held July 24th at ... the most highly regarded, emerging leaders in their field ...
(Date:7/25/2014)... July 25, 2014 (HealthDay News) -- The human brain ... of dehydration, a new study finds. Although ... in England have found that the brain compensates by ... blood. "This research has helped us understand a ... extreme exercise in extreme conditions," study first author Steven ...
(Date:7/25/2014)... York, ON (PRWEB) July 25, 2014 A ... Michael’s Hospital revealed that 39 percent of all children in ... a dentist. , The survey looked at 2,505 children during the ... all around four years of age. The final result was ... any dental care. Many of these children were from lower-income families ...
Breaking Medicine News(10 mins):Health News:Multiple States Crack Down on Heroin Epidemic 2Health News:Distractions Seem More Troublesome With Age 2Health News:Dr. Kerri Luzzo of the Reproductive Science Center of Providence Receives “40 Under Forty Award" for Outstanding Professional Accomplishments and Community Outreach 2Health News:Human Brain Has Coping Mechanism for Dehydration 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 3
... By Jenifer Goodwin HealthDay Reporter , ... of parents with health insurance say they haven,t gotten ... new survey in Ohio finds. Parents of kids ... those with public health insurance such as Medicaid or ...
... Medical Center,s Reinberger Neuroscience Intensive Care Unit (NSU) has ... This is a top honor from the American Association ... The NSU joins four other intensive care units ... been recognized with Beacon Awards: Medical Intensive Care ...
... The roots of cassava ( Manihot esculenta ) serve ... of people in many arid regions of the world, ... Unfortunately the roots of commercial cassava cultivars are ... in these regions. In addition to programs designed ...
... HealthDay Reporter , MONDAY, Oct. 4 (HealthDay News) -- ,A ... prompt healthy lifestyle changes in families, new research sUggests. ... program where they were given a list of health-promoting activities ... the family diet, exercising more as a family and reducing ...
... Diagnostic X-rays may increase the risk of developing ... at the University of California, Berkeley,s School of Public ... with acute lymphoid leukemia (ALL) had almost twice the ... X-rays compared with children who did not have leukemia. ...
... When girls with symptoms of autism or ADHD seek professional ... and there is a real risk that they will not ... training is needed in this area,particularly in the public sector, ... thesis focuses primarily on 100 girls who, before reaching adulthood, ...
Cached Medicine News:Health News:Many Kids Not Getting Recommended Care: Survey 2Health News:Many Kids Not Getting Recommended Care: Survey 3Health News:University Hospitals Case Medical Center's neuroscience intensive care unit earns Beacon Award 2Health News:Using cassava to address vitamin A deficiency 2Health News:Companies Can Motivate Families to Live Healthier 2Health News:Companies Can Motivate Families to Live Healthier 3Health News:X-rays linked to increased childhood leukemia risk 2Health News:X-rays linked to increased childhood leukemia risk 3Health News:X-rays linked to increased childhood leukemia risk 4Health News:Girls with autism or ADHD symptoms not taken seriously 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: